503B Outsourcing Facilities Report 2025

Welcome to interactive presentation, created with Publuu. Enjoy the reading!

©2025 RXinsider | RXinsider Market Intelligence Group | 2025

503B History and Timeline

The Drug Quality and Security Act, signed into law on

November 27, 2013, created a new section 503B in the

Federal Food, Drug, and Cosmetic Act. Under section 503B,

a compounder can become an outsourcing facility.

SCA Pharmaceuticals became the first FDA

registered 503B compounding facility.

753 patients in 20 states were diagnosed with

a fungal infection after receiving contaminated

methylprednisolone acetate from New England

Compounding Center. The CDC reported 64 deaths,

with a total of 793 patients affected nationwide.

2013

2012

2016

2018

Prescription Requirement is added under Section

503A of the Federal Food, Drug, and Cosmetic Act.

2019

Industry guidelines are created by registered

outsourcing facilities on the Compounding and

Redistribution of Radiopharmaceuticals.

Section 503A Bulks List Final Rule Questions and

Answers; Small Entity Compliance Guide is established.

2023

Prohibition on Wholesaling is added under Section

503B of the Federal Food, Drug, and Cosmetic Act.

2020

Biological products that were approved under

the Federal Food, Drug, and Cosmetic (FD&C)

Act transitioned to being licensed under

the Public Health Service (PHS) Act.

2024

FDA established Modernization Initiatives to

create a unified human foods program, revamp

field operations, and introduce additional reforms.

2025

Interim Policy on Compounding Using Bulk

Drug Substances is added under Section 503A

of the Federal Food, Drug, and Cosmetic Act

As of March 31, 2025, a total of 89 503B

companies are registered.

Made with Publuu - flipbook maker